Staging classification of lung cancer. A critical evaluation.

The International System for Staging Lung Cancer has been validated as a prognostic index and questioned regarding the implications of factors that require further study. As technology for evaluating the anatomic extent of disease is increasingly refined, the accuracy of clinical staging is greatly improved and provides a major benefit for individualized treatment selection. Advancing knowledge of the origin and development of lung tumors presents the challenge of appropriate integration of this body of science into clinical practice.

[1]  V. Rusch,et al.  Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. , 2000, The Journal of thoracic and cardiovascular surgery.

[2]  C. Mountain,et al.  Regional lymph node classification for lung cancer staging. , 1997, Chest.

[3]  R. Coleman,et al.  Proceedings of a National Cancer Institute workshop: PET in oncology--a clinical research agenda. , 1994, Radiology.

[4]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[5]  H. Koeffler,et al.  Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. , 2001, Cancer research.

[6]  R. Coleman,et al.  PET in lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  D. Ferrigno,et al.  Prognostic value of stage grouping and TNM descriptors in lung cancer. , 2000, Chest.

[8]  K. O'Byrne,et al.  Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer , 2000, British Journal of Cancer.

[9]  T. Naruke,et al.  Lymph node mapping and curability at various levels of metastasis in resected lung cancer. , 1978, The Journal of thoracic and cardiovascular surgery.

[10]  K. Yasumoto,et al.  Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis. , 1997, The Annals of thoracic surgery.

[11]  S. Miyoshi,et al.  Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. , 2000, The Annals of thoracic surgery.

[12]  S. Adak,et al.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. , 2000, The New England journal of medicine.

[13]  C. Angeletti,et al.  Tumour necrosis factor- α and transforming growth factor- β are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL -2-mediated neovascularization , 2000, British Journal of Cancer.

[14]  Y. Morishita,et al.  Mediastinal lymph node evaluation by computed tomographic scan in lung cancer. , 2001, The Journal of cardiovascular surgery.

[15]  Tzei-Yi Lin,et al.  Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. , 2001, Cancer research.

[16]  Harvey I. Pass,et al.  Lung cancer : principles and practice , 1996 .

[17]  J. Howington,et al.  Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. , 2000, The Annals of thoracic surgery.

[18]  G. V. von Schulthess,et al.  Detection of extrathoracic metastases by positron emission tomography in lung cancer. , 1998, The Annals of thoracic surgery.

[19]  T. Abe,et al.  Expression of nucleolar protein p120 in human lung cancer: difference in histological types as a marker for proliferation. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  M. Riggs,et al.  Effect of HER2/neu expression on survival in non-small-cell lung cancer. , 2001, Clinical lung cancer.

[21]  G. Silvestri,et al.  Diagnosis and staging of lung cancer. , 2000, Clinics in chest medicine.

[22]  D. Fuchs,et al.  Neopterin: a prognostic variable in operations for lung cancer. , 2000, The Annals of thoracic surgery.

[23]  W. Richards,et al.  Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. , 2000, The Annals of thoracic surgery.

[24]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[25]  P Grenier,et al.  CT demonstration of the 1996 AJCC-UICC regional lymph node classification for lung cancer staging. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[26]  Non-small cell lung cancer: FDG-PET imaging. , 1999, Journal of thoracic imaging.

[27]  D. Carter TNM Classification of Malignant Tumors , 1998 .

[28]  F MURRAY,et al.  Diagnosis and treatment of lung cancer. , 1955, Geriatrics.

[29]  J. Roth,et al.  Gene replacement strategies for treating non-small cell lung cancer. , 2000, Seminars in radiation oncology.

[30]  R. Livingston,et al.  [A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[31]  H. Hansen,et al.  Surgery in limited stage small cell lung cancer. , 1999, Cancer treatment reviews.

[32]  S. Kondo,et al.  Evaluation of new TNM lung cancer classification. , 2000, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

[33]  L. Dominioni,et al.  Stage I nonsmall cell lung carcinoma , 2000, Cancer.

[34]  J. Vansteenkiste,et al.  Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease). , 1996, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[35]  H. Wada,et al.  Prognostic significance of polysialic acid expression in resected non-small cell lung cancer. , 2001, Cancer research.

[36]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[37]  B. Thompson,et al.  MR imaging of pulmonary and mediastinal malignancies. , 2000, Magnetic resonance imaging clinics of North America.

[38]  M. Green,et al.  The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? , 1999, Chest.

[39]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[40]  C. Mountain,et al.  A new international staging system for lung cancer. , 1987, Chest.

[41]  D. Harpole,et al.  Staging techniques for lung cancer. , 2000, Chest surgery clinics of North America.

[42]  P. Valk,et al.  Factors associated with false-positive staging of lung cancer by positron emission tomography. , 2000, The Annals of thoracic surgery.

[43]  J. Luketich,et al.  The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small-cell lung cancer. , 2001, Clinical lung cancer.

[44]  J. Deslauriers,et al.  Carcinoma of the lung. Evaluation of satellite nodules as a factor influencing prognosis after resection. , 1989, The Journal of thoracic and cardiovascular surgery.

[45]  Y. Nishiwaki,et al.  The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. , 1999, The Journal of thoracic and cardiovascular surgery.

[46]  O. Stoeltzing,et al.  Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer , 2000, British Journal of Cancer.

[47]  Metabolic staging of lung cancer. , 2000, The New England journal of medicine.

[48]  E. Patz,et al.  Lung cancer and positron emission tomography with fluorodeoxyglucose. , 2000, Lung cancer.

[49]  L. Kostakoglu,et al.  Nuclear medicine imaging of lung cancer. , 2000, Radiologic clinics of North America.

[50]  Y. Nishiwaki,et al.  Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[51]  Beahrs Oh,et al.  The American Joint Committee on Cancer. , 1984 .

[52]  C. Mountain Surgical treatment of lung cancer , 1991 .

[53]  V. Zoumpourlis,et al.  Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics. , 2001, Cancer research.

[54]  M. O'Doherty,et al.  Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. , 1999, The Annals of thoracic surgery.

[55]  P. Zanen,et al.  Survival in synchronous vs. single lung cancer: upstaging better reflects prognosis. , 2000, Chest.

[56]  V. Capelozzi,et al.  Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas. , 2000, Japanese journal of clinical oncology.